Clinical Trial Update: A Clinical Trial to Test How Well Two Drugs, QAW039 and Montelukast Work Both Individually and Together, to Target Allergic Rhinitis Using an Environmental Exposure Chamber [Phase 2]

View source ↗

Summary

A completed Phase 2 trial evaluated QAW039 (fevipiprant) and montelukast, alone and in combination, for allergic rhinitis using an environmental exposure chambe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• Montelukast (Montelukast)
• QAW039

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Allergic Rhinitis | Phase 2 | Status: COMPLETED